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SCIENTIFIC OPINION 
Scientific Opinion on lipase from a genetically modified strain of Aspergillus 
oryzae (strain NZYM-AL)
1 
EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids (CEF)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The food enzyme considered in this opinion is a lipase (triacylglycerol lipase; EC 3.1.1.3) produced with a 
genetically modified strain of Aspergillus oryzae. The genetic modifications do not give rise to safety concern. 
The food enzyme contains neither the production organism nor recombinant DNA. The lipase is intended to be 
used in a number of food manufacturing processes, such as baking, brewing and other cereal-based processes, 
and immobilised onto an inert support for oils and fats processing. The dietary exposure was assessed according 
to the Budget method. The food enzyme did not induce gene mutations in bacteria nor micronuclei in human 
peripheral blood lymphocytes. Therefore, there is no concern with respect to genotoxicity. The systemic toxicity 
was assessed by means of a 90-day subchronic oral toxicity study in rodents. A No Observed Adverse Effect 
Level was derived, which, compared with the dietary exposure, results in a sufficiently high Margin of Exposure. 
The  allergenicity  was  evaluated  by  searching  for  similarity  of  the  amino  acid  sequence  to  those  of  known 
allergens. The Panel considered that the likelihood of food allergic reactions to the enzyme is low and therefore 
does not give rise to safety concern. Based on the genetic modifications performed, the manufacturing process, 
the compositional and biochemical data provided and the toxicological studies, this food enzyme does not give 
rise to safety concern under the intended conditions of use. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following a request from  the European Commission, the EFSA Panel on  Food Contact Material, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on 
the food enzyme lipase (triacylglycerol lipase; EC 3.1.1.3) produced with the genetically modified 
Aspergillus oryzae strain NZYM-AL.  
This A. oryzae strain lineage has a long history of use for the production of food enzymes. It has been 
modified  in  order  to  produce  and  secrete  lipase  and  to  prevent  or  decrease  the  production  of 
undesirable secondary metabolites. The genetic modifications do not give rise to safety concern. 
The food enzyme contains neither the production organism nor recombinant DNA, given the limits of 
detection.  
The food enzyme has been characterised by determining the temperature and pH optima and the 
thermo-stability. Its composition is verified by measuring the content of protein, ash, water, heavy 
metals and Total Organic Solids. The A. oryzae parental strain has been modified in order to prevent 
the  production  of  cyclopiazonic  acid  and  to  decrease  the  potential  production  of  kojic  acid.  The 
absence of cyclopiazonic acid, β-nitropropionic acid and kojic acid was demonstrated, given the limits 
of detection.  
The food enzyme is intended to be used in a number of food manufacturing processes, such as baking, 
brewing and other cereal-based processes, and immobilised onto an inert support for oils and fats 
processing. The typical uses and the recommended use levels for specific food processes have been 
provided. 
The Theoretical Maximum Daily Intake was calculated using the Budget method.  
The genotoxicity of the food enzyme was assessed by means of two in vitro assays (gene mutations in 
bacteria and in vitro micronucleus assay). The food enzyme, produced with the genetically modified 
A. oryzae strain NZYM-AL, did not induce gene mutations in bacteria with or without metabolic 
activation when tested under the conditions employed in the study as presented by the applicant. Nor 
did it induce micronuclei in cultured human blood lymphocytes under the test conditions employed for 
this study. The systemic toxicity was assessed by means of a 90-day subchronic oral toxicity study in 
rats. A No Observed Adverse Effect Level (NOAEL) was derived, which, compared with the dietary 
exposure, results in a sufficiently high Margin of Exposure.  
The allergenicity was evaluated by searching for similarity of the amino acid sequence to those of 
known allergens; no match was found. The CEF Panel considers that the likelihood of food allergic 
reactions to this lipase produced by this genetically modified strain of A. oryzae is low and, therefore, 
does not give rise to safety concern. 
Based  on  the  genetic  modifications  performed,  the  manufacturing  process,  the  compositional  and 
biochemical data provided and the toxicological studies, the Panel concluded that this food enzyme 
does not give rise to safety concern under the intended conditions of use. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Only food enzymes included in the Union list may be placed on the market as such and used in foods, 
in accordance with the specifications and conditions of use provided for in Article 7 (2) of Regulation 
(EC)  No  1332/2008
4  on food enzymes.   According to Regulation (EC) No  1332/2008 on food 
enzymes,  a  food enzyme which falls within the scope of Regulation (EC) No 1829/2003
5  on 
genetically modified food and feed should be authorised in accordance with that Regulation as well as 
under this Regulation.  
An application has been introduced by the company Novozymes A/S for the authorisation of the food 
enzyme lipase from a genetically modified strain of Aspergillus oryzae (strain NZYM-AL). 
Following  the  requirements  of  Article  12.1  of  Commission  Regulation  (EU)  No  234/2011
6 
implementing Regulation (EC) No 1331/2008
7, the Commission has verified that the application falls 
within the scope of the food enzyme Regulation and contains all the elements required under Chapter 
II of that Regulation. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The  European  Commission  requests  the  European  Food  Safety  Authority  to  carry  out  the  safety 
assessment on the food enzyme lipase from a genetically modified strain of Aspergillus oryzae (strain 
NZYM-AL) in accordance with Article 17.3 of Regulation (EC) No 1332/2008 on food enzymes. 
                                                       
4  Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and  
  Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/199, Directive 2000/13/EC, Council  
  Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7-15. 
5  Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically  
  modified food and feed. OJ L 268, 18.10.2003 p. 1-23. 
6  Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the  
  European Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes  
  and food flavourings. OJ L 64, 11.03.2011, p. 15-24. 
7  Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a  
  common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p. 1-6.  
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ASSESSMENT 
1.  Introduction 
Before January 2009, food enzymes other than those used as food additives were not regulated or were 
regulated  as  processing  aids  under  the  legislation  of  the  Member  States.  On  20  January  2009, 
Regulation  (EC)  No  1332/2008  on  food  enzymes  entered  into  force.  This  Regulation  applies  to 
enzymes that are added to food to perform a technological function in the manufacture, processing, 
preparation,  treatment,  packaging,  transport  or  storage  of  such  food,  including  enzymes  used  as 
processing aids. Regulation (EC) No 1331/2008 established European Union (EU) procedures for the 
safety  assessment  and  the  authorisation  procedure  of  food  additives,  food  enzymes  and  food 
flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:  
(i)  it  does  not  pose  a  safety  concern  to  the  health  of  the  consumer  at  the  level  of  use 
proposed;  
(ii)  there is a reasonable technological need; and  
(iii)  its use does not mislead the consumer.  
All food enzymes currently on the EU market and intended to remain on that market as well as all new 
food enzymes shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) 
and an approval via an EU list. 
The Guidance on submission of a dossier on a food enzyme for evaluation by EFSA (EFSA CEF 
Panel, 2013) lays down the administrative, technical and toxicological data required. 
In the case of enzymes produced with genetically modified microorganisms (GMM), the guidance on 
the risk assessment of GMM and their products intended for food and feed use (EFSA GMO Panel, 
2011) applies.  
The assessment of a GMM aims to evaluate the safety of the food enzyme related to the genetic 
modifications. This starts from the evaluation of the safety of the parental/recipient and donor strains, 
e.g. regarding their capability to produce undesirable metabolites. It also includes the assessment of 
the genetic modifications, specifically of the introduction of genes of concern and of genetic stability. 
Finally, the presence of the production organism and of its recombinant DNA in the final product is 
assessed. Special attention is paid to the presence of any recombinant genes of concern (e.g. antibiotic 
resistance genes), introduced during the development of the production strain. If the absence of the 
production strain and of the recombinant DNA has been confirmed, no extensive environmental risk 
assessment of the enzyme product is required. 
The following evaluation applies to the lipase (triacylglycerol lipase; EC 3.1.1.3) produced with the 
genetically modified strain of A. oryzae strain NZYM-AL. 
2.  Information on existing authorisations and evaluations 
The applicant reports that the Danish and French authorities have evaluated and authorised the use of 
the food enzyme produced with the genetically modified A. oryzae strain NZYM-AL for several food 
processes, such as oils and fats processing, baking and brewing processes. The Danish authority also 
sets out the conditions of use, including the dosages for specific foods; up to 200 Kilo Lipase Units 
(KLU)/kg  triacylglycerols  for  interesterification,  2.5 KLU/kg  flour  for  baking  processes  and 
36.4 KLU/kg barley for brewing processes.  
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3.  Technical data 
3.1.  Identity of the food enzyme 
IUBMB nomenclature:   Triacylglycerol lipase  
Systematic name:   Triacylglycerol acylhydrolase  
Synonym:  Lipase 
IUBMB No:   EC 3.1.1.3  
CAS No:   9001-62-1  
EINECS No:   232-619-9. 
3.2.  Chemical parameters 
The lipase produced with the genetically modified Aspergillus oryzae strain NZYM-AL is a single 
polypeptide chain of 274 amino acids. The molecular mass, derived from the amino acid sequence, 
was calculated to be 29.9 kDa.  
Data on the chemical parameters and the protein homogeneity status of the food enzyme have been 
provided for four batches, three batches to be used for commercialisation and one batch (PPW 29840) 
used for the toxicological tests (Table 1).  
The average TOS content of the three batches for commercialisation was 22.2 % (w/w); the values 
ranged from 20.4 to 23.4 % (Table 1). The TOS content is a calculated value derived as 100 % - % 
water - % ash. The four food enzyme batches presented in Table 1 are ultra-filtrated concentrates 
without any added diluents. Batch PPW 29840 has been less concentrated than the other three batches 
(Table 1). 
The average enzyme activity/TOS ratio of the three batches for commercialisation was 3.7 KLU/mg 
TOS; the values ranged from 3.6 to 3.8 KLU/mg TOS (Table 1). Considering the low variability of the 
enzyme  activity/TOS  ratio  in  the  three  food  enzyme  batches  (LAFR-batches,  Table  1)  for 
commercialisation,  the  average  activity/TOS  ratio  of  3.7 KLU/mg  TOS  was  used  for  subsequent 
calculations. 
Aspergillus oryzae, as a species, is known to have the potential to produce undesirable secondary 
metabolites  such  as  cyclopiazonic  acid  (CPA),  β-nitropropionic  acid  (NPA)  and  kojic  acid  (KA) 
(Blumenthal, 2004). Accordingly, these mycotoxins must be checked in the final food enzyme from A. 
oryzae (FAO/WHO, 2006). A. oryzae, as a species, belongs to the Aspergillus flavus group, which is 
known to have a gene cascade for the biosynthesis of aflatoxins; however, A. oryzae strains never 
produced aflatoxins under any known fermentation conditions (Lee et al., 1991; Blumenthal, 2004). 
The parental strain has been modified by γ-irradiation mutagenesis, resulting in the deletion of gene 
clusters  required  for  the  synthesis  of  the  mycotoxins  CPA  and  aflatoxin  (AFL).  UV  irradiation 
mutagenesis resulted in a reduced potential (15 % of the original) to produce KA. None of these three 
species-specific mycotoxins (CPA, NPA and KA) was detected in the food enzyme (Table 1) by liquid 
chromatography/tandem mass spectrometry (LC-MS/MS).  
The protein homogeneity status of food enzyme was also investigated by sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis. The apparent molecular mass based on this 
technique is about 36 kDa (compared with the calculated molecular mass of 29.9 kDa). According to 
the applicant, this is most likely due to glycosylation, a common feature of proteins of Aspergillus. 
The two bands of lower molecular mass seen in the four samples analysed were explained by the  
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applicant to be most likely due to different glycosylation variants. The gels presented for the four 
batches were comparable. 
The food enzyme was tested for other enzyme activities, i.e. -amylase, glucoamylase, protease and β-
glucanase activities, which were below the detection limits of the employed methods, except for the β-
glucanase activity (Table 1). 
Table 1:   Compositional data of the food enzyme  
Parameter  Unit  Batches 
LAFR 690-693  LAFR 698  LAFR 699-701  PPW 29840 
(a) 
Lipase activity  KLU/g batch 
(b)  766  871  833  232 
Protein  % (w/w)  17.8  19.7  20.2  6.6 
Ash  % (w/w)  0.7  0.4  0.5  2.2 
Water  % (w/w)  78.9  76.9  76.10  88.4 
Total Organic 
Solids (TOS) 
(c) 
% (w/w)  20.4  22.7  23.4  9.4 
Activity/mg TOS  KLU/mg TOS  3.8  3.8  3.6  2.5 
Pb  mg/kg batch  ND
(d)  ND
(d)  ND 
(d)  ND 
(d) 
As  mg/kg batch  ND
(d)  ND
(d)  ND 
(d)  ND 
(d) 
Cd  mg/kg batch  ND
(d)  ND  ND 
(d)  ND 
(d) 
Hg  mg/kg batch  ND
(d)  ND
(d)  ND 
(d)  ND 
(d) 
Antimicrobial 
activity 
_  ND
(d)  ND
(d)  ND 
(d)  ND 
(d) 
Production strain  CFU/g batch  ND
(d)  ND
(d)  NA
(e)  ND 
(d) 
Cyclopiazonic 
acid 
mg/kg batch  ND
(d)  ND
(d)  ND 
(d)  ND 
(d) 
Kojic acid  mg/kg batch  ND
(d)  ND
(d)  ND
(d)  ND
(d) 
β-Nitropropionic 
acid 
mg/kg batch  ND
(d)  ND
(d)  ND 
(d)  ND 
(d) 
Antifoam agents  mg/kg batch  151  1 432  403  115 
-Amylase  FAU(F)/g batch
 (f)  ND 
(d)  ND 
(d)  ND 
(d)  ND 
(d) 
Glucoamylase  AGU/g batch
 (g)  ND 
(d)  NA 
(e)  NA
(e)  ND 
(d) 
Protease  HUT/g batch
 (h)  ND 
(d)  ND 
(d)  ND 
(d)  ND 
(d) 
β-Glucanase  BGU/g batch 
(i)  0.291  0.255  0.122  0.065 
(a):  Batch used for the toxicological tests. 
(b):  KLUL: Kilo Lipase Units (see Section 3.3). 
(c):  TOS calculated as 100 % - % water - % ash. 
(d):  ND: not detected, i.e. below the limits of detection (Pb: 0.5 mg/kg; As: 0.1 mg/kg; Cd: 0.05 mg/kg; Hg: 0.03 mg/kg; 
CPA: 0.1 mg/L; KA: the limits of detection ranged from 0.01 to 0.03 mg/kg; NPA: the limits of detection ranged from 
0.2 to 0.27 mg/kg; -Amylase: 0.33 FAU(F)/g. Glucoamylase: 0.825 AGU/g. Protease: 196 HUT/g). 
(e):  NA: not analysed. 
(f):  FAU(F): Fungal alpha-Amylase Units (relative to an internal enzyme standard “F”). 
(g):  AGU: AmyloGlucosidase Units. 
(h):  HUT: Haemoglobin Units Tyrosine. 
(i):  BGU: Beta-Glucanase Units. 
 
 
The food enzyme complies with the microbiological criteria as laid down in the general specifications 
and  considerations  for  enzymes  used in  food  processing  (FAO/WHO,  2006), which stipulate  that 
Escherichia coli and Salmonella species are absent in 25 g of sample and total coliforms are no more 
than 30 CFU (Colony Forming Units) per gram.   
   Lipase from Aspergillus oryzae strain NZYM-AL 
 
EFSA Journal 2014;12(12):3778   
 
8 
The applicant has provided information on the identity of the antifoam agents and the Panel considers 
that the use of these does not give rise to safety concern. 
The data provided regarding compositional batch-to-batch-variability are considered sufficient. Table 
1 shows that the food enzyme batch PPW 29840 (less ultra-filtrated) used for the toxicological assays 
has a lower activity/mg TOS  value and a higher level of inorganic constituents compared with the 
three batches for commercialisation (LAFR-batches, Table 1). Consequently, this food enzyme batch 
(PPW  29840)  is  cruder  than  the  three  batches  produced  for  commercialisation  and  is  therefore 
considered suitable for toxicological testing.  
3.3.  Properties of the food enzyme 
The triacylglycerol lipase from A. oryzae strain NZYM-AL is intended to be used both in hydrolysis 
and in interesterification processes. In the presence of water, the enzyme catalyses the hydrolysis of 
the  ester  linkages  in  triacylglycerols,  resulting  in  the  generation  of  glycerol,  free  fatty  acids, 
diacylglycerols and monoacylglycerols. In the absence of water, or at a very low concentration of 
water, interesterification, i.e. the exchange of free fatty acids in positions 1 and 3 between two or more 
triacylglycerols, is catalysed. The lipase does not require any co-factor. 
The lipase activity is quantified by using a pH-stat titration system and is expressed in Kilo Lipase 
Units/g (KLU/g). One Lipase Unit (LU) is the amount of enzyme which releases 1 µmol of titratable 
butyric  acid  per  minute  under  the  given  standard  conditions  (reaction  conditions:  pH  7.0, 
temperature 30 °C,  reaction  time,  at  least  1.5  minutes).  One  LU  corresponds  to  the  international 
definition of an enzyme unit. In the assay, tributyrin is used as substrate and its cleavage results in the 
formation of butyric acid, which causes a change in pH. The reaction rate, and therefore the enzyme 
activity, is determined by measuring the volume of titrant added to the reaction system per minute to 
keep the pH constant.   
The activity of the lipase has been characterised depending on temperature and pH. The lipase is very 
active at temperatures ranging from 30 °C to 73 °C (with an optimum of 60 °C at pH 6) and within a 
pH range of 6 to 8 (with an optimum of pH 7 at 30 °C). The thermo-stability of the food enzyme was 
tested over the range 10 °C to 100 °C after pre-incubation at different temperatures at pH 6 for 30 
minutes. The activity itself was measured under standard conditions. The food enzyme shows 50 % 
residual activity remaining at 65 °C; no activity remains after 30 minutes at temperatures above 80 °C. 
3.4.  Information on the source materials 
3.4.1.  Information relating to the GMM 
3.4.1.1.  Characteristics of the recipient and parental microorganisms  
The production strain is the fungus Aspergillus oryzae. A. oryzae strains are not considered suitable for 
the QPS (Qualified Presumption of Safety) because of the potential for mycotoxin production (EFSA 
BIOHAZ Panel, 2013). The parental strain lineage, A. oryzae A1560, has a long history of use for the 
production of food enzymes. The recipient strain, A. oryzae JaL828, has been developed from the 
parental  strain,  A.  oryzae  A1560,  through  a  series  of  modification  steps,  including  classical 
mutagenesis  and  genetic  modification  (not  described  for  confidentiality  reasons).  The  classical 
mutagenesis  steps  included  γ-irradiation  mutagenesis,  resulting  in  the  deletion  of  gene  clusters 
required for the synthesis of the mycotoxins cyclopiazonic acid and aflatoxin, and UV irradiation 
mutagenesis, resulting in a drastically reduced potential (15 % of the original) to produce kojic acid  
Southern analysis confirmed the absence of antibiotic resistance genes which were used during the 
genetic modifications of the recipient strain.  
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3.4.1.2.  Characteristics of the donor organisms  
The plasmid vector used for the transformation of the recipient strain contained elements to control 
expression of the gene of interest as well as to ensure integration of the introduced DNA into the 
recipient strain chromosome. The DNA introduced into the recipient strain did not contain antibiotic 
resistance genes.  
3.4.1.3.  Description of the genetic modification process  
The production strain, A. oryzae NZYM-AL, was developed from the recipient strain, JaL828, through 
transformation with a plasmid vector and selection of the transformants on appropriate medium. 
The production strain differs from the recipient strain by the synthesis and secretion of lipase. 
3.4.1.4.  Safety aspects of the genetic modification: information relating to the GMM and comparison 
of the GMM with its conventional counterpart 
In comparison with the parental strain, A1560, the recipient strain, JaL828, has lost the potential for 
CPA production ability and has shown a reduced potential production of KA. 
The final production strain, NZYM-AL, differs from the recipient strain in the synthesis and secretion 
of lipase. 
The presence of the gene encoding lipase in strain NZYM-AL was verified by Southern analysis; this 
indicated that multiple copies of the gene were integrated into the chromosomal DNA of the recipient. 
In order to estimate the number of copies, a quantitative real-time polymerase chain reaction (PCR) 
was carried out in triplicate by using three different concentrations of DNA.  
Southern analysis of the DNA production strain from three independent food enzyme preparation 
batches  at  the  end  of  pilot-scale  fermentation  confirmed  the  genetic  stability  of  the  genetic 
modifications.  
The genetic modifications do not give rise to safety concern. 
3.4.1.5.  Safety of the environment 
Neither the production strain nor its recombinant DNA was detected in the final product (see Section 
3.5.2). Accordingly, as the food enzyme belongs to Category 2 of the guidance on risk assessment of 
genetically modified microorganisms and their products (EFSA GMO Panel, 2011), environmental 
exposure of the genetically modified microorganism or its DNA is negligible and hence no further 
environmental risk assessment is required. 
3.5.  Manufacturing process 
The  manufacturing  process  comprises  a  fermentation  process  and  a  downstream  processing.  A 
comprehensive dataset related to the manufacturing process including a flow diagram was provided. 
The  food  enzyme  is  manufactured  in  accordance  with  Regulation  (EC)  No  852/2004
8  and  in 
accordance  with  current Good  Manufacturing  Practice (GMP) .  According  to  the  applicant ,  the 
manufacturing process is certif ied according to Food Safety Systems Certification 22000 (FSSC 
22000) and ISO 9001. 
                                                       
8  Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food 
additives. OJ L 226, 25.6.2004, p. 3-21.  
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3.5.1.  Information relating to the fermentation process 
The  food  enzyme  is  produced  by  a pure  culture  in  contained, submerged,  fed-batch  fermentation 
system with conventional process controls in place. The identity and the purity of the culture are 
checked at each transfer step from frozen vials to the end of fermentation.  
3.5.2.  Information relating to the downstream processing 
The  downstream  processing  includes  recovery,  purification  and  concentration.  The  food  enzyme 
produced is recovered from the fermentation broth after biomass separation via filtration. Further 
purification and concentration involve a series of filtration steps including ultrafiltration and final 
germ filtration.  
The production strain could not be detected in a test using 1 g of three independent liquid batches 
tested in triplicate by liquid culturing in non-selective medium for four days followed by growth on 
selective  solid  agar  plates  for  four  days  at  a  suitable  temperature  favouring  the  growth  of  the 
production strain in relation to the background flora. No recombinant DNA was detected starting with 
1 g of three samples of the concentrated product before formulation obtained from three independent 
production batches and tested in triplicate. Analysis was performed by PCR, amplifying  c.a. 1 kb 
recombinant fragment spanning the deletion of an endogenous gene introduced during the genetic 
modification of the parental strain. 
3.5.3.  Information relating to immobilised enzyme  
The lipase from A. oryzae strain NZYM-AL is proposed to be used in oils and fats processing in the 
form of immobilised enzyme. To achieve immobilisation, the stabilised lipase concentrate is adsorbed 
onto  a  solid  support.  The  particles  are  dried  and  sieved  and  finally  filled  in  fixed-bed  reactors 
(columns), four or six reactors, in line. Each reactor contains a sieve plate (mesh filter) located at its 
base to prevent leakage of the immobilised enzyme out of the reactor. The oil is filtered through a bag 
filter  at  the  end  of  the  last  reactor  to  remove  any  fines  present  in  the  final  product.  A  final 
deodorisation step is applied after the interesterification process.  This assures denaturation of any 
enzyme residue. 
3.6.  Reaction and fate in food 
This  food  enzyme,  in  the  presence  of  water,  catalyses  the  hydrolysis  of  the  ester  linkages  in 
triacylglycerols,  resulting  in  the  generation  of  glycerol,  free  fatty  acids,  diacylglycerols  and 
monoacylglycerols.  In  the  absence  of  water,  or  at  a  very  low  concentration  of  water,  the 
interesterification catalysed by the lipase results in the exchange of free fatty acids in positions 1 and 3 
between two or more triacylglycerols.  
The  data  provided  indicate  that  the  lipase  is  denatured  during  the  intended  baking  and  brewing 
processes. However, in fats and oils processing, the lipase is intended to be used as immobilised 
enzyme, being retained in the fixed-bed reactors, and is therefore not expected to be released into the 
final food.  
Owning to the substrate specificity of the lipase, no unintended reaction products in foods are to be 
expected. Furthermore, the food enzyme has been tested for alpha-amylase, glucoamylase, protease 
and  β-glucanase  activities  showing  the  absence  of  significant  side  activities  relevant  for  food 
applications. Therefore, no unintended reaction products are to be expected.  
3.7.  Case of need and intended conditions of use 
The food enzyme is intended to be used in a number of food manufacturing processes, such as baking, 
brewing and other cereal-based processes and immobilised onto an inert support for oils and fats 
processing. Typical uses provided by the applicant are listed in Table 2.   
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Table 2:   Typical uses and recommended maximum use levels of the food enzyme as provided by 
the applicant 
Process  Recommended dosage of the food enzyme 
Baking processes and other cereal-based processes  Up to 2.5 KLU/kg of flour, corresponding to 0.68 mg 
TOS/kg  (2.5 KLU/3.7 KLU/mg  TOS  (3.7  is  the 
average of the three commercial batches))  
Brewing  processes  and  other  cereal-based  beverage 
processes 
Up to 55 KLU/kg of grain, corresponding to 14.9 mg 
TOS/kg  (55  KLU/3.7 KLU/mg  TOS  (3.7  is  the 
average of the three commercial batches)) 
Oils and fats processing  Immobilised, 200 KLU/kg of oils/fats, corresponding 
to 54.1 mg TOS/kg (200 KLU/3.7 KLU/mg TOS (3.7 
is the average of the three commercial batches)) 
 
In baking processes, the food enzyme is used in order  to improve the characteristic of the  dough 
(strength and stability), facilitating its handling. The food enzyme is added together with other raw 
materials during the dough formation step. 
In brewing processes,  the  food enzyme  is  used in order  to reduce the turbidity of the wort;  the 
hydrolysed lipids move to the spent grain fraction, resulting in a low lipid content of the wort. The 
food enzyme is added to the mash tun at the beginning of the mashing step. 
In oils and fats processing, the lipase is intended to be used as immobilised enzyme in a fixed-bed 
reactor for the enzymatic interesterification of oils and fats, modifying their melting properties and 
making them suitable for the production of margarines, shortenings and other products. 
According to the applicant, the food enzyme is used at the minimum dosage necessary to achieve the 
desired reaction, in accordance with Good Manufacturing Practice (GMP). The dosage applied in 
practice by a food manufacturer depends on the particular process (see Table 2). 
4.  Dietary exposure 
The dietary exposure assessment was performed according to the Budget method (FAO/WHO, 2009). 
This  method  has  been  used  as  a  screening  method  in  assessing  food  additives  by  the  JECFA 
(FAO/WHO, 2001) and for assessments within the EU Scientific Cooperation (SCOOP) Task 4.2 (EC, 
1998). The approach is based on the maximising assumptions that 25 % of consumed solid foods and 
25 % of consumed beverages would be manufactured using the food enzyme and that all of the food 
enzyme would remain in the final processed food products. It is expected that the enzyme would be 
inactivated and/or residues of the food enzyme would be removed in the course of the production and 
processing of final food products. However, considering that the products resulting from the use of the 
food enzyme may be used in a variety of applications, as ingredients of food and/or beverages, the 
Panel considered it appropriate to use this conservative upper-bound screening approach to estimate 
the  dietary  exposure.  If  required,  e.g.  in  the  case of  low  margins  of exposure  resulting  from  the 
application of this conservative approach, a more refined exposure assessment would be performed.  
The Panel followed the principles of the stepwise approach, which was used to assess the Theoretical 
Maximum Daily Intake (TMDI).  
The estimation is based on the following assumptions:  
  The levels of consumption of foods and beverages considered are maximum physiological 
levels that can be consumed each day, i.e. the daily consumption of 0.1 L/kilogram (kg) body 
weight (bw) of non-milk beverages and the daily consumption of 100 kcal/kg bw from foods 
(equivalent to 0.05 kg/kg bw based on an estimated energy density of 2 kcal/g). These levels  
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correspond to the daily consumption of 6 L of non-milk beverages and 3 kg of food by a 
person with a body weight of 60 kg (typical adult) and a daily consumption of 1.5 L of non-
milk beverages and 750 g of food by a person with a body weight of 15 kg (a typical three-
year-old child) (FAO/WHO, 2009). 
  The level of food enzyme present in foods and non-milk beverages is assumed to be the 
highest recommended maximum use level of the food enzyme (expressed in milligrams (mg) 
of  TOS  per  kg  of  product  (or  substrate,  or  ingredient))  reported  by  the  applicant  in  any 
representative  category  of  foods  and  beverages.  The  highest  recommended  maximum  use 
levels are 0.68 mg TOS per kg wheat flour or cereal dry matter for baking and other cereal-
based processes and 14.9 mg TOS per kg grain (e.g. barley, malt, wheat, rice) for brewing 
processes (Table 2). The lipase that is intended to be used as immobilised enzyme in a fixed-
bed reactor for oils and fat processing is assumed to be retained in the reactor and thus not 
present in the final food. 
  The proportion of solid foods and beverages that may contain the food enzyme is set generally 
at 25 %. The default proportion (25 %) of beverages and solid food that could contain the 
enzyme was considered adequate. Although lipase may be used in a variety of solid foods and 
beverages that could represent more than 25 % of processed foods, it is unlikely that a person 
would systematically choose all processed foods with the same enzyme added, even taking 
into consideration brand loyalty. This assumes that a typical adult weighing 60 kg consumes 
daily 1.5 L of beverages and 750 g of solid foods containing the food enzyme. 
If  the  food  enzyme  is  proposed  for  products  specifically  designed  for  infants  or  young 
children,  ad  hoc  conservative  exposure  estimates  must  be  made,  specifically  taking  into 
account these population groups. Otherwise, the very conservative approach described above 
is considered to cover both adults and children. 
Assuming the conservative scenario described above and also that all processed foods and beverages 
would contain 70 %
9 and 17 %
10 of cereal or grain ingredients, respectively, the Panel estimated that 
the theoretical maximum daily intake of the food enzyme from the genetically modified  A. oryzae 
strain would be approximately 0.0693 mg TOS/kg bw (0.68 mg TOS/kg  0.05 kg/kg bw  25 %  
70 %) + (14.9 mg TOS/kg  0.1 L/kg
11 bw  25 %  17 %). 
5.  Toxicological data 
The  toxicological  assays  were  performed  with  a  food  enzyme  batch  (PPW  29840;  see  Table  1) 
representative of the other three food enzyme batches.  
Genotoxicity testing 
In order to investigate the potential to induce gene mutations in bacteria, an Ames test was performed 
in accordance with OECD Test Guideline 471 (OECD, 1997) and following Good Laboratory Practice 
(GLP) in four strains of Salmonella typhimurium (TA1535, TA100, TA1537, TA98) and Escherichia 
coli WP2uvrA, in the presence or absence of metabolic activation by S9 mix, and applying the “plate 
incorporation assay”. Two experiments were carried out using six different concentrations of the food 
enzyme, appropriate positive control chemicals and deionised water as a negative control. The highest 
concentration  was  5 000 μg  dry  matter  plate  (corresponding  to  4  052 μg  TOS/plate).  Slight 
cytotoxicity was observed only for TA100 with S9 mix, evident as a slight reduction in the number of 
revertants. No significant increase in revertant colonies above control values was observed in any 
                                                       
9  100 g flour gives 140 g bread.  
10 In general, 1 kg of grain gives 6 kg of beer. 
11 It is assumed that the densities of beverages are approximately 1.  
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strains either with or without metabolic activation. Therefore, it was concluded that the food enzyme 
has no mutagenic activity, under the conditions employed.  
The  in  vitro  micronucleus  assay  was  carried  out  in  accordance  with  OECD  Test  Guideline  487 
(OECD, 2010) and following GLP. The food enzyme was tested in the in vitro micronucleus test using 
human peripheral blood lymphocytes both with and without metabolic activation with S9 mix.  A 
maximum concentration of 5 000 μg food enzyme/ml final culture concentration (corresponding to 
470 μg TOS/ml final culture concentration) was selected. Purified water was used as solvent and 
appropriate positive controls were included. Scoring was done with 1 000 cells in duplicate cultures. 
In  experiment  one,  the  highest  concentration  (5 000 g  food  enzyme/ml  culture  corresponding  to 
470 μg TOS/ml culture) in the absence and presence of metabolic activation induced approximately 
0 % and 11 % reduction in replication index, respectively. There were no indications of an increase in 
micronucleated cells at the three tested concentrations compared with the vehicle control either in the 
absence or in the presence of metabolic activation. In experiment two, the highest concentration (5 000 
g food enzyme/ml culture corresponding to 470 μg TOS/ml culture) in the absence of metabolic 
activation, induced 4% reduction in replication index. There were no indications of an increase in 
micronucleated cells at the three tested concentrations compared with the vehicle control either in the 
absence or in the presence of metabolic activation. It was concluded that the food enzyme did not 
induce chromosomal aberration in cultured human peripheral blood lymphocytes when tested at levels 
of  up  to  5 000 μg  food  enzyme/ml  (corresponding  to  470 μg  TOS/ml)  under  the  experimental 
conditions employed. 
Repeated dose toxicity testing 
A 90-day sub-chronic oral toxicity study was performed in accordance with OECD Test Guideline 408 
and following GLP (OECD, 1998). Four groups of 10 male and 10 female HSDHan™:WIST strain 
rats were given by gavage a dose of 5 ml/kg bw/day purified water, a 10 % solution, a 33 % solution 
or an undiluted food enzyme solution of the food enzyme for 13 weeks. The doses were equivalent to 
49.1, 162 and 491 mg TOS/kg bw/day. 
Body weight slightly increased only in males (8.5 %, 11.8 % and 3.5 % in the low-, mid- and high-
dose group, respectively). The increases were not statistically significant and were not dose related; 
therefore, they are not considered of toxicological relevance.  
In  haematology,  females  receiving  the  middle  and  the  highest  dosages  showed  a  statistically 
significant  increase  in  mean  cell  volumes,  while  males  treated  with  the  same  dosages  showed  a 
statistically  significant  reduction  in  the  mean  cell  haemoglobin  concentration.  In  addition,  a 
statistically significant reduction in the platelet distribution width in males receiving the highest dose 
was observed. As these changes were within the historical control values and not accompanied by 
other related haematological changes they are not considered of safety concern.  
The microscopic examination revealed a dose-related increase in the incidence of pancreatic lobular 
atrophy in males of the middle- and high-dose groups. These increases in incidence were above the 
historical control values (in a range 0 - 20 %) for both groups and the severity was also slightly 
increased in the high-dose group. It cannot be ruled out that these findings are adverse. Consequently, 
the Panel derived a NOAEL on the low dose level of 49.1 mg TOS/kg bw/day. 
6.  Allergenicity 
Potential allergenicity of lipase was assessed by comparing its amino acid sequence with those of 
known allergens in accordance with the scientific opinion on the assessment of allergenicity of GM 
plants and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified 
Organisms (EFSA GMO Panel, 2010). Using higher than 35 % identity in a window of 80 amino acids  
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as the criterion, no match was found. No food allergic reactions to lipase have been reported in the 
literature. 
Consequently, the CEF Panel considers that the likelihood of food allergic reactions to  this lipase, 
produced with this genetically modified strain of Aspergillus oryzae, is low and therefore does not 
give rise to safety concern. 
7.  Discussion 
The parental strain, Aspergillus oryzae A1560, has a long history of use for the production of food 
enzymes. The recipient strain, JaL828, was developed from the parental strain through a series of 
modification steps, including classical mutagenesis and genetic modifications. The production strain, 
NZYM-AL, contains a recombinant gene encoding lipase. Multiple copies were randomly integrated 
into the genomic DNA as part of the plasmid vector. The introduced trait is well known and does not 
trigger a safety concern. No sequences that cause concern remained. Neither the production strain nor 
the recombinant genes are detected in the final products by methods considered adequate by the CEF 
Panel. 
The information provided on the manufacturing of the food enzyme, i.e. the fermentation conditions 
and  the  steps  employed  for  isolation  and  purification,  is  considered  sufficient.  The  available 
compositional data, including experimental evidence of the absence of potential contaminants such as 
mycotoxins, sufficiently demonstrate the identity and the purity of the food enzyme. The reported 
batch-to-batch variability is considered acceptable. 
This application includes the use of immobilised enzyme for oils and fats processing. The lipase is 
adsorbed onto a solid support and packed into several fixed-bed reactors, each one equipped with a 
sieve plate located at its base that prevents any leakage. Furthermore, the use of a bag filter at the end 
of the last reactor would assure the removal of any fines present in the final product. The Panel noted 
that a final deodorisation step is applied to the final product and such treatment would denature any 
remaining enzyme. 
Exposure assessment is performed for the processes in which the lipase is intended to be used in non-
immobilised form. Dietary exposure estimates were calculated using the Budget method by assuming 
that the lipase is used at its maximum recommended dosage and the entire added food enzyme remains 
in the final food. Based on these assumptions and taking into consideration the total intake (Section 4), 
the TMDI is 69.3 µg TOS/kg bw. The Panel is aware that the exposure assessment performed is highly 
conservative because it does not take into account factors such as inactivation and removal of the food 
enzyme during food processing. 
The food enzyme did not induce gene mutations in bacteria nor micronuclei in human peripheral blood 
lymphocytes. Therefore, it gives rise to no concerns with respect to genotoxicity. In the subchronic 90-
day study in rats, microscopic examination revealed an increase in the incidence of pancreatic lobular 
atrophy in males of the middle- and high-dose groups. These findings are dose related and as it cannot 
be ruled out that these findings are adverse, the Panel derived a NOAEL on the low dose level of 
49.1 mg TOS/kg bw/day. 
A  comparison  of  this  NOAEL  (49.1 mg  TOS/kg  body  weight)  with  the  TMDI,  calculated  to  be 
69.3 µg TOS/kg bw, results in a MOE of 708, which is found sufficiently high. 
The  CEF  Panel  considers  that  the  likelihood  of  food  allergic  reactions  to  the  lipase  from  this 
genetically modified strain of Aspergillus oryzae is low and, therefore, use of this enzyme does not 
give rise to safety concern.  
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CONCLUSIONS 
Based  on  the  genetic  modifications  performed,  the  manufacturing  process,  the  compositional  and 
biochemical data provided and the findings in the toxicological studies, the food enzyme “Lipase from 
a genetically modified strain of Aspergillus oryzae (strain NZYM-AL)” does not give rise to safety 
concern under the intended conditions of use. 
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ABBREVIATIONS 
AFL  aflatoxin 
AGU  AmyloGlucosidase Units 
BGU  Beta-Glucanase Unit 
bw  body weight 
CAS  Chemical Abstracts Service  
CFU  Colony Forming Unit 
CPA  cyclopiazonic acid 
DNA  deoxyribonucleic acid 
EC  European Commission and Enzyme Commission 
EFSA  European Food Safety Authority 
EINECS  European Inventory of Existing Commercial Chemical Substances 
EU  European Union 
FAO  Food and Agricultural Organisation 
FAU(F)   Fungal alpha-Amylase Units (relative to an internal enzyme standard “F”). 
FSSC  Food Safety Systems Certification 
GLP  Good Laboratory Practice 
GMM  genetically modified microorganism 
GMO  genetically modified organisms 
GMP  Good Manufacturing Practice 
HUT   Haemoglobin Units Tyrosine. 
IUBMB  International Union of Biochemistry and Molecular Biology 
JECFA  Joint FAO/WHO Expert Committee on Food Additives 
KA  kojic acid 
kDa  kilodalton 
KLU  Kilo Lipase Unit  
LC-MS/MS  liquid chromatography/tandem mass spectrometry 
MOE  margin of exposure 
NA  not analysed 
ND  not detected 
NOAEL  No Observed Adverse Effect Level 
NPA  β-nitropropionic acid 
OECD  Organisation for Economic Co-operation and Development 
PCR  polymerase chain reaction 
QPS  Qualified Presumption of Safety 
SDS-PAGE  sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
TMDI  Theoretical Maximum Daily Intake 
TOS  Total Organic Solids 
WHO  World Health Organization 
 